文献速递免疫规划

四价重组流感疫苗在韩国成人中的免疫原性与安全性:III期随机研究

Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.
PubMed 文献 · Vaccine · 2025-08-05

这项III期、平行、随机、改良双盲、阳性对照、多中心研究在韩国三个三级医疗中心比较了单剂肌注四价重组流感疫苗(RIV4)与当地已上市四价灭活流感疫苗(IIV4,Fluarix®四价)在≥18岁成人中的免疫原性与安全性。300名完成研究的参与者总体平均年龄46.1岁,RIV4组对A/H1N1、A/H3N2、B/Victoria系和B/Yamagata系的接种后HAI抗体几何平均倍数上升分别为32.0、13.2、6.1和5.3,IIV4组分别为22.3、8.0、4.7和3.4;RIV4的血清转化与IIV4相当或更高,6个月随访期间未报告SAE、AESI或死亡。

要点

  • RIV4组对A/H1N1、A/H3N2、B/Victoria系、B/Yamagata系的HAI抗体几何平均倍数上升分别为32.0、13.2、6.1、5.3。
  • IIV4组对应四种毒株的HAI抗体几何平均倍数上升分别为22.3、8.0、4.7、3.4。
  • RIV4的血清转化与IIV4相当或更高;接种后30分钟内未报告即时不 solicited AE,6个月随访未报告SAE、AESI或死亡。

核心结论

  • 在≥18岁韩国成人中,单剂肌注RIV4的免疫原性(血清转化)与IIV4相当或更高,且6个月随访期间未报告SAE、AESI或死亡。

研究设计与样本

  • III期、平行、随机、改良双盲、阳性对照、多中心研究,在韩国三个三级医疗中心于2021-22年北半球流感季开展。
  • 参与者按1:1随机接受单剂肌注RIV4或IIV4(Fluarix®四价),通过交互式应答技术(IRT)集中分配;参与者、研究者及负责采样、安全性评估和免疫原性检测的人员设盲。
  • 300名完成研究的参与者总体平均年龄为46.1岁。

主要发现

  • 接种后HAI抗体几何平均倍数上升:RIV4组对A/H1N1、A/H3N2、B/Victoria系、B/Yamagata系分别为32.0、13.2、6.1、5.3;IIV4组分别为22.3、8.0、4.7、3.4。
  • RIV4的血清转化与IIV4相当或更高。
  • 接种后30分钟内未报告即时不 solicited AE;6个月随访期间未报告SAE、AESI或死亡。

关键数值与推荐

  • RIV4组对A/H1N1、A/H3N2、B/Victoria系、B/Yamagata系的接种后HAI抗体几何平均倍数上升分别为32.0、13.2、6.1、5.3。
  • IIV4组对A/H1N1、A/H3N2、B/Victoria系、B/Yamagata系的接种后HAI抗体几何平均倍数上升分别为22.3、8.0、4.7、3.4。
  • RIV4的血清转化与IIV4相当或更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quadrivalent recombinant influenza vaccine (RIV4) is indicated for active immunization against influenza virus in adults (≥18 years) in countries where it is currently registered. This Phase III, parallel, randomized, modified double-blind, active controlled, multi-center study was designed to compare the immunogenicity and safety of single dose intramuscular RIV4 with a locally-licensed quadrivalent-inactivated influenza vaccine (IIV4, Fluarix® quadrivalent) in participants aged ≥18 years during 2021-22 Northern Hemisphere influenza season at three tertiary care centers in South Korea. Participants were randomized (1:1) to receive single dose intramuscular RIV4 or IIV4. All participants were centrally assigned to randomized study intervention using an interactive response technology (IRT). Participants, investigators, and the staff in-charge of the sampling, safety assessment and immunogenicity assays were blinded. The overall mean age of 300 participants who completed the study was 46.1 years. The post-vaccination geometric mean fold-rise of HAI antibodies were 32.0, 13.2, 6.1, and 5.3 in RIV4 group, and 22.3, 8.0, 4.7, and 3.4 in IIV4 group for the A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage strains, respectively. Seroconversion in RIV4 was comparable or higher than IIV4. Neither immediate unsolicited AEs were reported within 30 min of vaccination nor SAEs, AESIs nor deaths were reported during the 6-month follow-up. Clinical Trial Registration:ClinicalTrials.gov number - NCT05144945.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Choi WS, Lee J, Ottaviano C, et al. Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study. Vaccine. 2025. PMID: 40752250. doi:10.1016/j.vaccine.2025.127521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。